The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress

Michael A. Irvine, Andrew Scholey, Rebecca King, Rachel Gillings, David Vauzour, Stephen J. Demichele, Tapas Das, Keith A. Wesnes, Brad Sutton, Aedin Cassidy, Andrew Pipingas, John F. Potter, Glyn Johnson, David White, Ryan Larsen, Neal J Cohen, Anne Marie Minihane

Research output: Contribution to journalArticle

Abstract

Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.

Original languageEnglish (US)
Pages (from-to)591-601
Number of pages11
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume4
DOIs
StatePublished - 2018

Fingerprint

Neurogenesis
Cognition
Eicosapentaenoic Acid
Docosahexaenoic Acids
Omega-3 Fatty Acids
Atrophy
Blood Vessels
Dementia
Hippocampus
Fatty Acids
Erythrocytes
Biomarkers
Placebos
Magnetic Resonance Imaging
Urine
Diet
Health
Brain
Research
Pharmaceutical Preparations

Keywords

  • Cocoa flavan-3-ols
  • Cognition
  • Dementia
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Hippocampus
  • Magnetic resonance imaging
  • Mild cognitive impairment
  • Subjective memory impairment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial : Design and progress. / Irvine, Michael A.; Scholey, Andrew; King, Rebecca; Gillings, Rachel; Vauzour, David; Demichele, Stephen J.; Das, Tapas; Wesnes, Keith A.; Sutton, Brad; Cassidy, Aedin; Pipingas, Andrew; Potter, John F.; Johnson, Glyn; White, David; Larsen, Ryan; Cohen, Neal J; Minihane, Anne Marie.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 4, 2018, p. 591-601.

Research output: Contribution to journalArticle

Irvine, MA, Scholey, A, King, R, Gillings, R, Vauzour, D, Demichele, SJ, Das, T, Wesnes, KA, Sutton, B, Cassidy, A, Pipingas, A, Potter, JF, Johnson, G, White, D, Larsen, R, Cohen, NJ & Minihane, AM 2018, 'The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 4, pp. 591-601. https://doi.org/10.1016/j.trci.2018.08.001
Irvine, Michael A. ; Scholey, Andrew ; King, Rebecca ; Gillings, Rachel ; Vauzour, David ; Demichele, Stephen J. ; Das, Tapas ; Wesnes, Keith A. ; Sutton, Brad ; Cassidy, Aedin ; Pipingas, Andrew ; Potter, John F. ; Johnson, Glyn ; White, David ; Larsen, Ryan ; Cohen, Neal J ; Minihane, Anne Marie. / The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial : Design and progress. In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018 ; Vol. 4. pp. 591-601.
@article{c1f2cda1d270465aa783ccd45486eb1d,
title = "The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress",
abstract = "Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.",
keywords = "Cocoa flavan-3-ols, Cognition, Dementia, Docosahexaenoic acid, Eicosapentaenoic acid, Hippocampus, Magnetic resonance imaging, Mild cognitive impairment, Subjective memory impairment",
author = "Irvine, {Michael A.} and Andrew Scholey and Rebecca King and Rachel Gillings and David Vauzour and Demichele, {Stephen J.} and Tapas Das and Wesnes, {Keith A.} and Brad Sutton and Aedin Cassidy and Andrew Pipingas and Potter, {John F.} and Glyn Johnson and David White and Ryan Larsen and Cohen, {Neal J} and Minihane, {Anne Marie}",
year = "2018",
doi = "10.1016/j.trci.2018.08.001",
language = "English (US)",
volume = "4",
pages = "591--601",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial

T2 - Design and progress

AU - Irvine, Michael A.

AU - Scholey, Andrew

AU - King, Rebecca

AU - Gillings, Rachel

AU - Vauzour, David

AU - Demichele, Stephen J.

AU - Das, Tapas

AU - Wesnes, Keith A.

AU - Sutton, Brad

AU - Cassidy, Aedin

AU - Pipingas, Andrew

AU - Potter, John F.

AU - Johnson, Glyn

AU - White, David

AU - Larsen, Ryan

AU - Cohen, Neal J

AU - Minihane, Anne Marie

PY - 2018

Y1 - 2018

N2 - Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.

AB - Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.

KW - Cocoa flavan-3-ols

KW - Cognition

KW - Dementia

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Hippocampus

KW - Magnetic resonance imaging

KW - Mild cognitive impairment

KW - Subjective memory impairment

UR - http://www.scopus.com/inward/record.url?scp=85056169124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056169124&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2018.08.001

DO - 10.1016/j.trci.2018.08.001

M3 - Article

AN - SCOPUS:85056169124

VL - 4

SP - 591

EP - 601

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -